FIG 1.

Antigen-presenting-cell (APC) gating strategy. (A) Single, viable PBMCs positive for HLA-DR and negative for the lineage markers CD3, CD19, and CD56. FSC, forward scatter; SSC, side scatter. (B) HLA-DR⁺ CD3⁻ CD19⁻ PBMCs were distinguished into CD14⁺ monocytes and CD14⁻ APCs. (C) Monocytes were subdivided based on CD16 expression into CD14⁺ CD16⁻ classical monocytes (I) and CD14⁺ CD16⁺ intermediate monocytes (II). (D) CD14⁻ APCs were gated based on CD16 expression to distinguish CD14 CD16⁺ myeoloid dendritic cells (DCs) (III) (CD16 mDCs). (E) CD14⁻ CD16⁻ APCs were further subdivided into CD14⁻ CD16⁻ CD1c⁺ (IV) (type 1 myeloid DC [CD1c mDCs], also known as BDCA1 mDCs), CD14⁻ CD16⁻ BDCA3⁺ (V) (type 2 mDCs or BDCA3 mDCs), and CD14⁻ CD16⁻ BDCA2⁺ (VI) (plasmacytoid DCs [pDCs]).